Helius Medical Technologies (NASDAQ:HSDT) Trading Down 5.8% – Should You Sell?

Helius Medical Technologies, Inc. (NASDAQ:HSDTGet Free Report) traded down 5.8% on Wednesday . The company traded as low as $0.61 and last traded at $0.64. 121,735 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 6,598,582 shares. The stock had previously closed at $0.68.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “hold” rating on shares of Helius Medical Technologies in a research note on Wednesday, October 16th.

Check Out Our Latest Stock Analysis on Helius Medical Technologies

Helius Medical Technologies Price Performance

The company’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $0.66. The company has a market capitalization of $21.68 million, a PE ratio of -0.10 and a beta of 1.50.

Helius Medical Technologies (NASDAQ:HSDTGet Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.99) EPS for the quarter. Helius Medical Technologies had a negative net margin of 1,764.74% and a negative return on equity of 244.82%. The company had revenue of $0.05 million during the quarter.

About Helius Medical Technologies

(Get Free Report)

Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise.

Further Reading

Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.